News

Upstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).
Chronic obstructive pulmonary disease (COPD) is a lung condition that often hides in plain sight. You may think you're ...
Monsoon illnesses are seen every year, and they need a holistic combat plan. The first thing you can do to protect yourself ...
The Minnesota Pollution Control Agency issued an air quality alert Friday, July 11, for northwest and north central Minnesota. The alert takes effect 6 a.m. and runs until 6 p.m. Friday. Heavy ...
Merck to acquire respiratory drug maker, Verona Pharma for $10 billion: Rahway, New Jersey Thursday, July 10, 2025, 09:00 Hrs [IST] Merck, known as MSD outside of the United State ...
Researchers have found in two longitudinal cohorts that Incorporating chest CT imaging and respiratory symptoms into the ...
Kennel cough (Bordetella bronchiseptica) is something our pups are vaccinated against. This rampant respiratory virus can ...
Take better control of your children's asthma by knowing how you can provide them the best care and treatments.
Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for vereki ...
Symptoms can range from mild to severe depending on the type of infection you have, your age, and other factors. For instance, adults infected with rhinovirus (the most frequent cause of colds and a ...
Merck & Co. said Wednesday it will acquire London-based Verona Pharma in a $10 billion all-cash deal, bolstering its respiratory treatment portfolio as the company moves to reduce long-term dependence ...
Many children continue to experience respiratory symptoms up to 14 years after treatment for protracted bacterial bronchitis, ...